Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Endothelin Clear all
Terminated Phase 4 Interventional Results available

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

NCT02253394
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan plus Spironolactone, Ambrisentan plus Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jun 26, 2026, 2:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol

NCT00006071
View directory record Official record
Conditions
Hypercholesterolemia, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 2 Interventional

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

NCT01399580
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Jun 26, 2026, 2:58 AM EDT
Recruiting Phase 3 Interventional

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244
View directory record Official record
Conditions
Acute Ischemic Stroke, Cerebral Stroke
Interventions
Drug: Normal Saline, Sovateltide
Drug
Lead sponsor
Pharmazz, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Tucson, Arizona • Carmichael, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 26, 2026, 2:58 AM EDT
Terminated Phase 2 Interventional

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

NCT00832507
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Cicletanine, Cicletanine Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 70 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
39
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Jun 26, 2026, 2:58 AM EDT
Terminated Phase 3 Interventional Results available

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

NCT00795639
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Sitaxsentan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Fountain Valley, California • Mather, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Jun 26, 2026, 2:58 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Endothelin Receptor Function and Acute Stress

NCT02116335
View directory record Official record
Conditions
Hypertension
Interventions
Bosentan, Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 3 Interventional Results available

Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

NCT01224210
View directory record Official record
Conditions
Portopulmonary Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
6
States / cities
La Jolla, California • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 4 Interventional Results available

Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)

NCT05373108
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Macitentan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

NCT01356849
View directory record Official record
Conditions
Chronic Kidney Disease, Diabetic Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
59
States / cities
Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glomerular Injury of Preeclampsia

NCT00275158
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
L-Arginine Supplementation
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

NCT03679780
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
BQ-788, BQ-123, L-Arginine, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Lactated Ringer's
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Jun 26, 2026, 2:58 AM EDT
Terminated Phase 2 Interventional

Tezosentan in Pulmonary Arterial Hypertension

NCT01077297
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tezosentan
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation

NCT00001624
View directory record Official record
Conditions
Hyperinsulinemia
Interventions
Insulin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 2:58 AM EDT
Terminated Phase 3 Interventional

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

NCT00120328
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
SPP301
Drug
Lead sponsor
Speedel Pharma Ltd.
Industry
Eligibility
21 Years to 80 Years
Enrollment
2,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2007 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 1 Interventional

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

NCT00613691
View directory record Official record
Conditions
Carcinoma
Interventions
SPI-1620
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2013 · Synced Jun 26, 2026, 2:58 AM EDT
Withdrawn Phase 3 Interventional

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Jun 26, 2026, 2:58 AM EDT
Completed No phase listed Observational

Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)

NCT01763892
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
5 Days to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 2 Interventional Results available

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

NCT00586820
View directory record Official record
Conditions
Myocardial Reperfusion Injury
Interventions
BQ-123, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer

NCT00617669
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, ZD4054, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
25
States / cities
Greenbrae, California • San Diego, California • Norwich, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jun 26, 2026, 2:58 AM EDT
Terminated Phase 3 Interventional Results available

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00879229
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Ambrisentan, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
51
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 2 Interventional

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)

NCT00111085
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
10
States / cities
Peoria, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Jun 26, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Bosentan on Exercise Capacity at High Altitude

NCT00432978
View directory record Official record
Conditions
Altitude, Pulmonary Hypertension
Interventions
Bosentan administration
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2007 · Synced Jun 26, 2026, 2:58 AM EDT